IGC Pharma Narrows Q3 Loss, but Cash Falls to $377K Ahead of CALMA Topline
IGC has more than doubled off its 52-week low of $0.08.
Summary
IGC Pharma's Q3 10-Q shows a $7.4 million nine-month loss, cash down to $377 thousand, and a $1.8 million working capital deficit, with CALMA Phase 2 topline data due December 2026/January 2027 as the key funding catalyst.
Key Events · Earnings and Guidance · IGC
-
Nine-Month Loss Widens to $7.4M
Net loss for the nine months ended September 30, 2026 was approximately $7.4 million versus $4.6 million a year earlier, driven by the absence of a $1.1 million asset-sale gain and $465 thousand of tax credits that boosted the prior-year period.
-
Cash Falls to $377K, Working Capital Deficit $1.8M
Cash and cash equivalents dropped 58% to $377 thousand from $900 thousand at December 31, 2025, while the working capital deficit widened to approximately $1.8 million from $366 thousand.
-
Runway Rests on Undrawn $12M O-Bank Facility
Management says current cash plus amounts expected under the $12 million O-Bank revolver (nothing drawn as of September 30, 2026; expires May 31, 2027; $1 million monthly draw limit) supports at least twelve months of operations, with no assurance of renewal.
-
CALMA Phase 2 Topline Due Dec 2026/Jan 2027
Enrollment is complete at 168 randomized participants; final dosing is expected to conclude mid-November 2026, followed by database lock, unblinding, and topline results in the December 2026/January 2027 window.
Analysis · IGC · Life Sciences
The quarter itself showed improvement: the three-month net loss narrowed to $2.0 million from $1.8 million... actually widened slightly, but operating loss fell 33% to $1.9 million as R&D and SG&A both dropped. The bigger issue is the balance sheet. Cash is down to $377 thousand with a $1.8 million working capital deficit, and the company is leaning on a $12 million O-Bank revolver (nothing drawn, expires May 31, 2027) plus ATM sales to stay funded. Management says it has at least twelve months of runway, but that assumes access to the facility and continued equity sales. The real swing factor is the CALMA Phase 2 trial in Alzheimer's agitation: enrollment is complete at 168 patients, dosing ends mid-November 2026, and topline data is expected December 2026/January 2027. That readout will determine whether the company can raise money on anything other than punitive terms. Its existing convertible notes convert at 75% of the lowest 10-day trading price, a structure that punishes shareholders if the stock falls.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IGC was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.2M. The 52-week trading range was $0.08 to $0.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.